Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection

首次发布于 2020 年 5 月 13 日

DNA Vaccine for Ragweed Allergic Adults

计划入组 25 人 · 首次发布于 2006 年 6 月 29 日

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

计划入组 42 人 · 首次发布于 2007 年 1 月 25 日

DV 601

Influenza virus vaccine (Dynavax)

TNF-alpha antagonist (Dynavax)

Dynavax GmbH

Germany

Dynavax Technologies

United States

Dynarex Corporation

United States

Dynavax Secures Exclusive License to Vaxart's Oral COVID-19 Vaccine in $25 Million Deal

Goldman Sachs Downgrades Dynavax on Competitive Pressures in Shingles and Hepatitis B Markets

Dynavax Reports Strong Growth with HEPLISAV-B Revenue Up 26% in 2024, Advances Pipeline Programs